Background
The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).
Objective
We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.
Methods
12-week data from a phase 2, randomized, double-blind, placebo-controlled, regimen-finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8), early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test.
Results
Patients (n = 404) were randomized to single (baseline) treatment regimen, n = 66; monthly, (baseline, weeks 4 and 8), n = 138; early, (baseline, weeks 1, 2, 4), n = 133; and placebo, n = 67. DLQI response was significantly higher in early, monthly, and single regimens than in placebo regimen (40.8 %, 33.6 %, and 13.1 % vs. 1.6 %, respectively; P < 0.001 for all).
Conclusion
Moderate to severe psoriasis patients receiving monthly and early treatment with secukinumab demonstrated improved HRQoL compared with placebo.